Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Université de Lille · Centre Hospitalier Universitaire de Lille · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
581
total citations
- FWCI
- 46.86
- Percentile
- 100%
- References
- 31
Citations per year
Authors
21- FMFranck MorschhauserCorresponding
Université de Lille, Centre Hospitalier Universitaire de Lille
- HTHervé Tilly
Inserm, Université de Rouen Normandie, Centre Henri Becquerel
- ACAristeidis Chaidos
Hammersmith Hospital, Imperial College London, Imperial College Healthcare NHS Trust
- PMPam McKay
Beatson West of Scotland Cancer Centre
- TPTycel Phillips
University of Michigan–Ann Arbor
Topics & keywords
Topics
Keywords
- Open label
- Medicine
- Follicular lymphoma
- Refractory (planetary science)
- Oncology
- Internal medicine
- Phases of clinical research
- Follicular phase
UN Sustainable Development Goals
- Partnerships for the goals
No related works found for this paper.